Eli Lilly Benelux – 50 year – 1969 – 2019: 50 year of Innovative healthcare in the heart of Brussels

The activities of the division located in Brussels contain three main areas: the medical department, the sales department, and the support departments. Through the medical department, which deals with the management of clinical studies, Lilly contributes greatly to the development of our new innovative medicines through intense collaboration with a vast network of academic and clinical researchers.

ELECTS is focused on importing and exporting to Europe and outsourcing the packaging and distribution of drugs for clinical trials (IMP-Investigational Medicinal Products).

Lilly Benelux is also part of the Pharma.be association, the Belgian General Association of the Pharmaceutical Industry, which brings together more than 130 innovative pharmaceutical companies based in Belgium and aims to provide patients with the fastest possible access to the most recent treatments from R&D.

Innovation at the heart of our mission

Aiming to accomplish their mission for improving people’s lives by developing treatments that meet those needs that are not yet fulfilled, Eli Lilly reinvests 21.6% of its sales into R&D. “Our company’s vision is to improve global health in the 21st century, which is why 7,500 of our employees work in our R&D sector”, Frédéric Clais, Country Manager for Belgium explains. “Investing in people and their development is key for success”, he says.

Belgium also plays an important role in the development of new medication. The company is collaborating with multiple hospitals and institutions. Last year, nearly 1,000 patients were included in these clinical trials. “Belgium wants to maintain its leadership position in the implementation of Clinical Trials. Together with the Minister of Health, we are striving to keep this competitive advantage and maintain Belgium as a leading country in clinical investigation. We do have a very open attitude for cooperation.”